241 related articles for article (PubMed ID: 17186531)
1. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
Oh WK; Tay MH; Huang J
Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531
[TBL] [Abstract][Full Text] [Related]
2. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
Berry W; Eisenberger M
Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Oh WK; Kantoff PW
Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for the treatment of hormone-refractory prostate cancer.
Chowdhury S; Burbridge S; Harper PG
Int J Clin Pract; 2007 Dec; 61(12):2064-70. PubMed ID: 17956560
[TBL] [Abstract][Full Text] [Related]
5. Future directions in the treatment of androgen-independent prostate cancer.
Petrylak DP
Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
[TBL] [Abstract][Full Text] [Related]
6. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.
Sternberg CN; Whelan P; Hetherington J; Paluchowska B; Slee PH; Vekemans K; Van Erps P; Theodore C; Koriakine O; Oliver T; Lebwohl D; Debois M; Zurlo A; Collette L;
Oncology; 2005; 68(1):2-9. PubMed ID: 15741753
[TBL] [Abstract][Full Text] [Related]
8. Current status and future prospects for satraplatin, an oral platinum analogue.
Choy H; Park C; Yao M
Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
10. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Sternberg CN; Petrylak DP; Sartor O; Witjes JA; Demkow T; Ferrero JM; Eymard JC; Falcon S; Calabrò F; James N; Bodrogi I; Harper P; Wirth M; Berry W; Petrone ME; McKearn TJ; Noursalehi M; George M; Rozencweig M
J Clin Oncol; 2009 Nov; 27(32):5431-8. PubMed ID: 19805692
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.
Cabrespine A; Guy L; Khenifar E; Curé H; Fleury J; Penault-Llorca F; Kwiatkowski F; Barthomeuf C; Chollet P; Bay JO
Urology; 2006 Feb; 67(2):354-9. PubMed ID: 16442593
[TBL] [Abstract][Full Text] [Related]
12. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
Nakabayashi M; Sartor O; Jacobus S; Regan MM; McKearn D; Ross RW; Kantoff PW; Taplin ME; Oh WK
BJU Int; 2008 Feb; 101(3):308-12. PubMed ID: 18184327
[TBL] [Abstract][Full Text] [Related]
13. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
Sava T; Basso U; Porcaro A; Cetto GL
Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
[TBL] [Abstract][Full Text] [Related]
14. Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
Lin AM; Ryan CJ; Small EJ
Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
16. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
Garmey EG; Sartor O; Halabi S; Vogelzang NJ
Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
[TBL] [Abstract][Full Text] [Related]
17. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
Di Lorenzo G; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hormone refractory prostate cancer.
Knox JJ; Moore MJ
Semin Urol Oncol; 2001 Aug; 19(3):202-11. PubMed ID: 11561988
[TBL] [Abstract][Full Text] [Related]
19. Management of hormone refractory prostate cancer: current standards and future prospects.
Oh WK; Kantoff PW
J Urol; 1998 Oct; 160(4):1220-9. PubMed ID: 9751323
[TBL] [Abstract][Full Text] [Related]
20. The role of chemotherapy in prostate cancer. Minireview.
Odrázka K; Vanásek J; Vaculíková M; Stejskal J; Filip S
Neoplasma; 2000; 47(4):197-203. PubMed ID: 11043822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
